Researchers have developed a programmable pill capable of delivering drugs directly to the required section of the intestine and releasing them at a pre-set time.

The new approach, described in a study published in the journal Nature Biomedical Engineering, could become an effective tool for treating hormonal disorders and other diseases that require targeted drug delivery through the gastrointestinal tract.

Conventional tablets and pills often do not work as intended, as part of the drug is degraded in the stomach and then enters the bloodstream without targeting a specific section of the intestine. This is especially important when therapy needs to act on specific regions of organs, or when the drug rapidly degrades in the stomach. The new pill solves this problem through an embedded microprogram that oversees when and where the active substance is released.

The key element of this system is a programmable block that responds to external signals and activates the pill’s opening mechanism. Such a mechanism enables control over the precise site of drug release in the small or large intestine, taking into account the patient’s individual physiological characteristics. Thus, the pill functions not only as a pill, but also as an intelligent carrier that ensures high precision of therapeutic action.

Researchers note the significance of this technology for treating hormonal disorders, such as pancreatic or thyroid gland dysfunctions, as well as other conditions where it is important for the drug to act specifically in a particular section of the intestine.

According to the authors of the aforesaid study, this programmable pill paves the way for personalized therapy, as it can be adjusted according to each patient’s individual needs.

In preliminary tests, the pills successfully delivered experimental drugs to designated sections of the intestines in animals and humans, demonstrating significant improvement in efficacy compared with traditional drug administration methods. This confirmed that this approach is not only at the conceptual phase, but also ready for further clinical trials.

As the technology develops, researchers hope that programmable pills will become part of standard therapeutic protocols and will be used not only for hormonal diseases, but also for many other conditions that require controlled and targeted drug delivery through the gastrointestinal tract.